ANI Pharmaceuticals (NASDAQ:ANIP) Issues FY24 Earnings Guidance

ANI Pharmaceuticals (NASDAQ:ANIP) issued an update on its FY24 earnings guidance on Friday morning. The company provided EPS guidance of $4.90-5.05 for the period, compared to the consensus EPS estimate of $4.72. The company issued revenue guidance of $594-602 million, compared to the consensus revenue estimate of $590.33 million. ANI Pharmaceuticals also updated its FY 2024 guidance to 4.900-5.050 EPS.

ANI Pharmaceuticals Stock Performance

Shares of ANIP opened at $61.44 on Monday. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.97 and a quick ratio of 3.07. ANI Pharmaceuticals has a 12-month low of $48.20 and a 12-month high of $70.81. The business’s fifty day moving average price is $58.66 and its 200 day moving average price is $61.49. The stock has a market capitalization of $1.29 billion, a PE ratio of 52.51 and a beta of 0.71.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on ANIP shares. Raymond James lifted their price objective on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the company an “outperform” rating in a research note on Wednesday, September 18th. Truist Financial raised their price objective on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a “hold” rating in a research note on Tuesday, October 22nd. Piper Sandler began coverage on ANI Pharmaceuticals in a research note on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. HC Wainwright reiterated a “buy” rating and set a $94.00 price target on shares of ANI Pharmaceuticals in a research report on Tuesday, September 17th. Finally, StockNews.com lowered ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and an average target price of $77.33.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.